Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Assets (2017 - 2025)

Historic Assets for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $209.7 million.

  • Sutro Biopharma's Assets fell 5359.82% to $209.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.7 million, marking a year-over-year decrease of 5359.82%. This contributed to the annual value of $387.2 million for FY2024, which is 1774.43% down from last year.
  • Per Sutro Biopharma's latest filing, its Assets stood at $209.7 million for Q3 2025, which was down 5359.82% from $262.4 million recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's Assets peaked at $489.0 million during Q2 2024, and registered a low of $209.7 million during Q3 2025.
  • Moreover, its 5-year median value for Assets was $385.6 million (2022), whereas its average is $377.8 million.
  • Per our database at Business Quant, Sutro Biopharma's Assets skyrocketed by 13299.95% in 2021 and then crashed by 5359.82% in 2025.
  • Quarter analysis of 5 years shows Sutro Biopharma's Assets stood at $341.4 million in 2021, then increased by 19.2% to $406.9 million in 2022, then rose by 15.68% to $470.7 million in 2023, then fell by 17.74% to $387.2 million in 2024, then plummeted by 45.85% to $209.7 million in 2025.
  • Its last three reported values are $209.7 million in Q3 2025, $262.4 million for Q2 2025, and $321.4 million during Q1 2025.